2/24
04:25 pm
syre
Spyre Therapeutics to Participate in Upcoming March Investor Conferences [Yahoo! Finance]
Low
Report
Spyre Therapeutics to Participate in Upcoming March Investor Conferences [Yahoo! Finance]
2/24
04:05 pm
syre
Spyre Therapeutics to Participate in Upcoming March Investor Conferences
Low
Report
Spyre Therapeutics to Participate in Upcoming March Investor Conferences
2/24
06:48 am
syre
Spyre Therapeutics (NASDAQ:SYRE) was upgraded by analysts at Leerink Partners to a "strong-buy" rating.
Low
Report
Spyre Therapeutics (NASDAQ:SYRE) was upgraded by analysts at Leerink Partners to a "strong-buy" rating.
2/20
01:10 pm
syre
Spyre Therapeutics (NASDAQ:SYRE) had its price target raised by analysts at Wells Fargo & Company from $40.00 to $50.00. They now have an "overweight" rating on the stock.
Low
Report
Spyre Therapeutics (NASDAQ:SYRE) had its price target raised by analysts at Wells Fargo & Company from $40.00 to $50.00. They now have an "overweight" rating on the stock.
2/20
12:22 pm
syre
Spyre Therapeutics (NASDAQ:SYRE) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $70.00 price target on the stock.
Medium
Report
Spyre Therapeutics (NASDAQ:SYRE) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $70.00 price target on the stock.
2/19
04:27 pm
syre
Spyre Therapeutics: Q4 Earnings Snapshot [Yahoo! Finance]
High
Report
Spyre Therapeutics: Q4 Earnings Snapshot [Yahoo! Finance]
2/19
04:02 pm
syre
Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
High
Report
Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
2/18
08:00 am
syre
Spyre Therapeutics Announces Presentations at the 21st ECCO Congress Supporting Differentiated Profile of SPY003 and Novel Animal Studies Demonstrating Superiority of Combination Approach
Low
Report
Spyre Therapeutics Announces Presentations at the 21st ECCO Congress Supporting Differentiated Profile of SPY003 and Novel Animal Studies Demonstrating Superiority of Combination Approach
2/16
12:38 pm
syre
Spyre Therapeutics (SYRE) Set POC Readout Priorities for 2026 [Yahoo! Finance]
Medium
Report
Spyre Therapeutics (SYRE) Set POC Readout Priorities for 2026 [Yahoo! Finance]
2/6
04:01 pm
syre
Spyre Therapeutics Announces Grants of Inducement Awards
Medium
Report
Spyre Therapeutics Announces Grants of Inducement Awards
1/26
03:18 pm
syre
Hot Picks: Biotech sector draws investor attention ahead of key data [BNN Bloomberg (Canada)]
Low
Report
Hot Picks: Biotech sector draws investor attention ahead of key data [BNN Bloomberg (Canada)]
1/23
04:00 pm
syre
Spyre Therapeutics Announces Grants of Inducement Awards
Low
Report
Spyre Therapeutics Announces Grants of Inducement Awards
1/17
06:31 am
syre
Spyre Therapeutics (SYRE) Valuation Check After Strong Recent Share Price Performance [Yahoo! Finance]
Low
Report
Spyre Therapeutics (SYRE) Valuation Check After Strong Recent Share Price Performance [Yahoo! Finance]
1/16
10:40 am
syre
Spyre Therapeutics (NASDAQ:SYRE) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $70.00 price target on the stock.
Low
Report
Spyre Therapeutics (NASDAQ:SYRE) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $70.00 price target on the stock.
1/15
12:06 pm
syre
Wall Street Bullish on Spyre Therapeutics, Inc. (SYRE) with Strong Buy Rating [Yahoo! Finance]
Low
Report
Wall Street Bullish on Spyre Therapeutics, Inc. (SYRE) with Strong Buy Rating [Yahoo! Finance]
1/12
08:27 am
syre
Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2 [Yahoo! Finance]
Medium
Report
Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2 [Yahoo! Finance]
1/12
08:00 am
syre
Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2
Medium
Report
Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2
1/11
10:02 am
syre
Spyre Therapeutics' CEO Sells 15,000 Shares [Yahoo! Finance]
Medium
Report
Spyre Therapeutics' CEO Sells 15,000 Shares [Yahoo! Finance]
1/8
04:05 pm
syre
Spyre Therapeutics Announces Grants of Inducement Awards
Low
Report
Spyre Therapeutics Announces Grants of Inducement Awards
12/19
05:58 am
syre
Spyre Therapeutics (NASDAQ:SYRE) was upgraded by analysts at Citigroup Inc. to a "strong-buy" rating.
Low
Report
Spyre Therapeutics (NASDAQ:SYRE) was upgraded by analysts at Citigroup Inc. to a "strong-buy" rating.
12/19
05:58 am
syre
Spyre Therapeutics (NASDAQ:SYRE) was upgraded by analysts at Mizuho to a "strong-buy" rating.
Low
Report
Spyre Therapeutics (NASDAQ:SYRE) was upgraded by analysts at Mizuho to a "strong-buy" rating.
12/17
07:01 pm
syre
Spyre Therapeutics (NASDAQ:SYRE) was given a new $53.00 price target on by analysts at Mizuho.
Medium
Report
Spyre Therapeutics (NASDAQ:SYRE) was given a new $53.00 price target on by analysts at Mizuho.
12/17
07:06 am
syre
Spyre Therapeutics (NASDAQ:SYRE) is now covered by analysts at Citigroup Inc.. They set a "buy" rating on the stock.
Low
Report
Spyre Therapeutics (NASDAQ:SYRE) is now covered by analysts at Citigroup Inc.. They set a "buy" rating on the stock.
12/5
04:05 pm
syre
Spyre Therapeutics Announces Grants of Inducement Awards
Medium
Report
Spyre Therapeutics Announces Grants of Inducement Awards
12/1
08:35 am
syre
Spyre Therapeutics (NASDAQ:SYRE) was upgraded by analysts at Jones Trading from a "hold" rating to a "buy" rating. They now have a $64.00 price target on the stock.
Medium
Report
Spyre Therapeutics (NASDAQ:SYRE) was upgraded by analysts at Jones Trading from a "hold" rating to a "buy" rating. They now have a $64.00 price target on the stock.